Warmuth Markus, President and CEO of Monte Rosa Therapeutics ($GLUE), sold shares on the open market five times over the past year, totaling about $380 thousand. His most recent sale occurred on March 2, 2026. These transactions rank 7,061st among 11,678 individual insiders, below the average sale amount of $8.6 million and 6.4 transactions per insider. Markus made no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 2, 2026 | Monte Rosa Therapeutics, Inc. | $GLUE | Warmuth Markus | President & CEO | S | Common Stock | 5466 | $17.92 | 613,471.0000 | 82,942,723 | 0.88% | 0.01% |
| Jan. 7, 2026 | Monte Rosa Therapeutics, Inc. | $GLUE | Warmuth Markus | President & CEO | S | Common Stock | 309 | $24.57 | 618,937.0000 | 82,942,723 | 0.05% | 0.00% |
| Jan. 7, 2026 | Monte Rosa Therapeutics, Inc. | $GLUE | Warmuth Markus | President & CEO | S | Common Stock | 1450 | $23.88 | 619,246.0000 | 82,942,723 | 0.23% | 0.00% |
| Jan. 7, 2026 | Monte Rosa Therapeutics, Inc. | $GLUE | Warmuth Markus | President & CEO | S | Common Stock | 3707 | $23.24 | 620,696.0000 | 82,942,723 | 0.59% | 0.00% |
| Jan. 2, 2026 | Monte Rosa Therapeutics, Inc. | $GLUE | Warmuth Markus | President & CEO | A | Stock Option (Right to Buy) | 406000 | $0.00 | 406,000.0000 | 82,942,723 | 9999.99% | 0.49% |
| Jan. 2, 2026 | Monte Rosa Therapeutics, Inc. | $GLUE | Warmuth Markus | President & CEO | A | Common Stock | 90000 | $0.00 | 634,538.0000 | 82,942,723 | 16.53% | 0.11% |
| Jan. 5, 2026 | Monte Rosa Therapeutics, Inc. | $GLUE | Warmuth Markus | President & CEO | S | Common Stock | 10135 | $15.17 | 624,403.0000 | 82,942,723 | 1.60% | 0.01% |
| Jan. 2, 2025 | Monte Rosa Therapeutics, Inc. | $GLUE | Warmuth Markus | President & CEO | A | Common Stock | 128000 | $0.00 | 544,538.0000 | 73,910,026 | 30.73% | 0.17% |
| Jan. 2, 2025 | Monte Rosa Therapeutics, Inc. | $GLUE | Warmuth Markus | President & CEO | A | Stock Option (Right to Buy) | 575000 | $0.00 | 575,000.0000 | 73,910,026 | 9999.99% | 0.78% |
| Jan. 2, 2024 | Monte Rosa Therapeutics, Inc. | $GLUE | Warmuth Markus | President & CEO | A | Stock Option (Right to Buy) | 346000 | $0.00 | 346,000.0000 | 51,396,961 | 9999.99% | 0.67% |